Burden of EGFR exon 20 insertion-mutated non-small-cell lung cancer
1 evidence topic · 3 sources
Summary
In a genomic-profiling series of 14,483 NSCLC cases, 263 (1.8%) had EGFR exon 20 insertions, representing 12% of EGFR-mutated cases. These are case-series frequencies, not population incidence rates. A retrospective comparison reported median real-world overall survival of 16.2 months with exon 20 insertions versus 25.5 months with common EGFR mutations. A separate analysis projected that PCR-based assays would miss approximately 50% of variants identified by NGS.